A COST Action to address challenges facing people with intellectual disabilities accessing cancer prevention and response services across Europe – Introducing CUPID - Cancer- Understanding Prevention in Intellectual Disabilities.
Keywords:Intellectual disabilities, COST Action, Cancer prevention, CUPID
COST Actions are grants provided by the European Union to support the establishment of networks of expertise to explore and address a scientific or social issue that impacts across Europe. This article introduces and describes one such action that started in October 2022 - CUPID - will address issues of policy and equity of access to cancer prevention initiatives by people with intellectual disabilities compared to the general population in Europe. With 82 individual members drawn from 30 countries CUPID will establish an interdisciplinary network of stakeholders representing carers, service providers, advocacy groups, educators, healthcare professionals, researchers and people with intellectual disabilities. The CUPID COST Action will be implemented over four years and will identify what needs to be addressed by the European Union and health and social services to improve cancer prevention among people with intellectual disabilities.
Berceht, C., Dedet, G., Klazinga, N., & Colombo, F. (2023). Inequalities in cancer prevention and care across Europe. The Lancet Oncol-ogy, 24(1), 10-11.
Brown M.J., Surfraz, M.N., Wroldsen, R., Popa, D. & Grund, R.M. (2017). Improving healthcare access for people with intellec-tual disabilities in four European countries. Learning Disability Practice, 20(6), 36-42.
Doyle,.A., O’Sullivan, M., Craig, S., & McConkey, R. (2022). Predictors of access to healthcare professionals for people with intellectual disability in Ireland. Journal of Intellectual Disabilities, 26(1), 3–17.
European Commission. (2020). Europe's Beating Cancer Plan Communication from the commission to the European Parliament and the Council. https://health.ec.europa.eu › eu_cancer-plan_en_0.
EU Science Hub (2022). Cancer in Europe: 5 things the data tells us. https://joint-research-centre.ec.europa.eu/jrc-news/cancer-europe-5-things-data-tells-us-2022-01-13_en.
Haveman, M., Perry, J., Salvador-Carulla, L., Noonan Walsh, P., Kerr, M., Van Schro-jenstein Lantman-de Valk, H., Van Hove, G., Berger, D.M., Azema, B., Buono, S., Cara, A.C., Germanavicius, A., Linehan, C., Määttä, T., Tossebro J. & Weber, G. (2011). Ageing and health status in adults with intellectual disabilities: Results of the European POMONA II study. Journal of Intellectual & Developmental Disability, 36(1), 49-60.
Heslop. P., Byrne, V., Calkin, R., Gielnik, K., & Huxor, A. (2020). Establishing a national mortality review programme for people with intellectual disabilities: The experi-ence in England. Journal of Intellectual Disabilities, 26(1), 264-280.
McCarron, M., Haigh, M. & McCallion, P. (2022). Health, Wellbeing and Social In-clusion: Ageing with an Intellectual Disa-bility in Ireland. Dublin. The Intellectual Disability Supplement to The Irish Longi-tudinal Study on Ageing 2017.
Portal, H., Schmidt, G., Crespo Fernández, R., Marcondes, B., Šveřepa, M., Dragičević, V. & Lysaght, D. (2020). Neglect and dis-crimination. Multiplied How Covid-19 af-fected the rights of people with intellectual disabilities and their families. Brussels. In-clusion Europe.
Satgé, D., Kempf, E., Dubois, J-B., Nishi, M. & Trédaniel, J. (2016). Challenges in Diagno-sis and Treatment of Lung Cancer in Peo-ple with Intellectual Disabilities: Current State of Knowledge. Lung Cancer Interna-tional.
Williamson, E.J, McDonald, H.I., Bhaskaran, K., et al. (2021). Risks of covid-19 hospital admission and death for people with learn-ing disability: population-based cohort study using the OpenSAFELY platform. British Medical Journal, BMJ 2021;374:n1592.
Willis, D. Samalin, E. & Satgé, D. (2018). Colo-rectal Cancer in People with Intellectual Disabilities. Oncology, 95:323-336.
How to Cite
Copyright (c) 2022 John Wells
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.